mRNA Therapeutics for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 72
Special Issue Editors
Interests: cancer therapy; drug delivery; layered double hydroxide nanoparticles; targeted delivery; nanomedicine
Special Issue Information
Dear Colleagues,
The Nobel Prizes for 2023 have just recognized the pivotal role of mRNA in revolutionizing vaccine development against COVID-19, underscoring the immense promise of mRNA technology, not only in infectious disease management but also in the realm of cancer treatment. In light of these recent groundbreaking achievements, we are thrilled to announce a Special Issue dedicated to exploring the potential of mRNA-based treatments for cancer. This Special Issue invites your contributions to further advance our understanding of this transformative approach for cancer therapy.
Our Special Issue seeks original research articles and reviews that delve into various aspects of mRNA therapeutics for cancer, including but not limited to:
- mRNA-based cancer vaccines: explore the development and mechanisms of personalized mRNA vaccines tailored to individual tumor profiles, and their potential to induce targeted immune responses against cancer cells;
- Clinical insights: share the latest findings from clinical trials and studies evaluating the efficacy and safety of mRNA-based cancer therapies, shedding light on their real-world applications;
- Synergy with existing treatments: investigate the potential synergy between mRNA therapies and other established cancer treatment modalities, such as immunotherapy and targeted therapies, to maximize patient outcomes;
- Innovations in delivery: highlight advancements in mRNA delivery technologies, including lipid nanoparticles and other innovative approaches, that enhance the precision and effectiveness of cancer therapeutics;
- Future directions: discuss the future directions and challenges in the field of mRNA therapeutics for cancer treatment, identifying promising avenues for further research.
Dr. Fatemeh Movahedi
Prof. Dr. Chengzhong Yu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA delivery
- cancer vaccine
- cancer immunotherapy
- personalized vaccine
- messenger RNA
